MTOR and hepatocellular carcinoma: Interestingly, immunosuppression is correlated with tumor occurrence risk (15), some HCC pathways are also the target of some immunosuppression agents, such as the mammalian target of rapamycin (mTOR) inhibitors (mTORi) (16, 17) (Figure 1).